<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>KRAS mutation is a negative predictive prognostic factor during <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> treatment with antiepidermal growth factor receptor antibodies </plain></SENT>
<SENT sid="1" pm="."><plain>For affected patients, new therapeutics must be explored </plain></SENT>
<SENT sid="2" pm="."><plain>Our objective was to study efficacy of two drugs with different mechanisms of action, everolimus (mTOR inhibitor) and <z:chebi fb="0" ids="49603">lapatinib</z:chebi> (<z:chebi fb="0" ids="38637">tyrosine kinase inhibitor</z:chebi>), in a mouse <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We chose a model obtained after engraftment of a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> originating from a human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> collection </plain></SENT>
<SENT sid="4" pm="."><plain>The patient was affected by a <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> resistant to cetuximab with KRAS mutation </plain></SENT>
<SENT sid="5" pm="."><plain>From a previous study in mice, we know that everolimus is a P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (P-gp) substrate and that a <z:chebi fb="0" ids="49603">lapatinib</z:chebi> pretreatment increases significantly (2.6-fold) everolimus AUC by inhibiting its intestinal P-gp efflux </plain></SENT>
<SENT sid="6" pm="."><plain>We hence tested the effect of these drugs alone or combined </plain></SENT>
<SENT sid="7" pm="."><plain>Mice bearing the xenografts were divided in four groups: control, <z:chebi fb="0" ids="49603">lapatinib</z:chebi>, everolimus, and L/E group (L/E: 2 days of <z:chebi fb="0" ids="49603">lapatinib</z:chebi> 200 mg/kg and then 3 days of everolimus 1 mg/kg) </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> volumes and treatment toxicities were evaluated </plain></SENT>
<SENT sid="9" pm="."><plain>Sixteen days after treatment initiation, the group L/E was the first one in which <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> volume average was significantly lower than the one of control group (193 ± 90 vs. 395 ± 171 mm(3) ; P = 0.0025) </plain></SENT>
<SENT sid="10" pm="."><plain>After 4 weeks of treatment, inhibition of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in <z:chebi fb="0" ids="49603">lapatinib</z:chebi>, everolimus, and L/E groups reached, respectively, 49, 53, and 57% </plain></SENT>
<SENT sid="11" pm="."><plain>Each drug showed significant antitumor activity </plain></SENT>
<SENT sid="12" pm="."><plain>Only moderate hematologic toxicity signs were observed </plain></SENT>
<SENT sid="13" pm="."><plain>These results lead to new perspectives for new oral drugs in metastatic KRAS-mutated <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> resistant to standard chemotherapy </plain></SENT>
</text></document>